# ZTi Biosciences

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/zti-biosciences

- Industry: Medical Devices & Equipment
- Headquarters: Daejeon-City, South Korea
- Website: www.zti-bio.com
- Total disclosed funding: $4.7M
- Latest round: Series A (Oct 1, 2021)
- Investors on record: 5

## About

Based in South Korea, ZTi Biosciences is a biotechnology firm focused on developing and manufacturing advanced solutions for research and clinical applications, including reagents and diagnostic kits.ZTi Biosciences, founded in 2020 in Daejeon-City, South Korea, specializes in biotechnology solutions. The company has engaged in a total of 4 deals, with its most recent funding occurring on April 4, 2022, when it successfully raised KRW 5,500.000 mn in a Series A round from investors including Kiwoom Investment and Korea Technology Finance Corporation. Jaden C. serves as the CEO.ZTi Biosciences specializes in the development and manufacturing of advanced biotechnology solutions aimed at enhancing research and clinical applications. The company’s core product offerings include innovative reagents and kits designed for molecular biology, including PCR reagents, DNA purification kits, and enzyme solutions that facilitate genetic analysis and diagnostics. These products are tailored for various end-use cases such as genetic research, disease diagnostics, and biopharmaceutical development, providing critical tools for laboratories and research institutions. ZTi Biosciences serves a diverse client base that includes academic research laboratories, healthcare providers, and pharmaceutical companies across North America, Europe, and parts of Asia. The solutions provided by ZTi Biosciences are essential for enhancing the accuracy and efficiency of molecular experiments and diagnostics.ZTi Biosciences generates revenue through direct sales of its products to research institutions, healthcare facilities, and commercial laboratories. The transaction structure predominantly involves B2B engagements where clients purchase products in bulk to meet their extensive research needs. The company offers various pricing plans for its reagent kits and diagnostic tools, with specific packages tailored for different scales of operation, from small research projects to large-scale clinical applications. As a result, ZTi Biosciences establishes long-term partnerships with its clients, ensuring consistent supply and support for ongoing research and development initiatives. These strategic relationships contribute to a stable revenue stream, reflecting the company’s commitment to supporting innovation in biotechnology.ZTi Biosciences plans to leverage recent funding to support the development of new products, including advanced diagnostic kits scheduled for release in early 2023. The company aims to expand its market presence in Europe and North America by the end of 2023, seeking to establish partnerships with local distributors. Recent funding from the Series A round will be pivotal in facilitating these initiatives, allowing ZTi Biosciences to enhance its product offerings and strengthen its market position.

## Funding rounds

- Series A, Oct 1, 2021, $4.7M — Korea Technology Finance Corporation, Kiwoom Investment, STIC Ventures, Tigris Investment
- Seed, Aug 11, 2020 — Spring Camp

## Investors

- Spring Camp (https://capitalatlas.ai/funds/spring-camp) — Seed
- Korea Technology Finance Corporation — Series A
- Kiwoom Investment (https://capitalatlas.ai/funds/kiwoom-investment) — Series A
- STIC Ventures (https://capitalatlas.ai/funds/stic-ventures) — Series A
- Tigris Investment (https://capitalatlas.ai/funds/tigris-investment) — Series A